Equinoxe Humeral Augmented Tray: 1st Shoulder Surgeries with New Solution for Proximal Humeral Bone Loss Performed in Florida

March 29, 2021

The Equinoxe Humeral Augmented Tray is the first implant of its kind. It replaces the greater tuberosity, a part of the shoulder that may be absent or deficient, fractured and/or reabsorbed due to disease.

The HAT was designed to be used in combination with the Equinoxe Platform Shoulder System for reverse procedures and was designed to help improve joint mechanics and stability for patients with proximal humeral bone loss. This unique implant can also be used with an extension for more severe proximal bone loss cases.

The first surgeries with the Humeral Augmented Tray were performed last week in Florida by Bradley Schoch, MD, of the Mayo Clinic in Jacksonville, and design team surgeon Howard Routman, DO, of JFK Medical Center in Lantana.

“The patients who need this implant have either previously undergone surgeries which failed, suffered fractures of the humeral head, or have congenital abnormalities that leave them with deficient tuberosities, which prevent them from doing what they want,” said Dr. Routman. “This implant allows them to return to what they love, and I feel very honored to have been part of the design team and one of the first to use this prosthesis.”

“We are very pleased to launch the Humeral Augmented Tray and excited to receive feedback from our surgeon colleagues and see its impact on patients. Its addition to the Equinoxe Shoulder family allows us to reach even more patients,” said Vice President of Extremities Chris Roche.

The design team includes Dr. Routman, Thomas Wright, MD, of the University of Florida in Gainesville, Fla.; Pierre-Henri Flurin, MD, of Surgical Clinic of Bordeaux in Merginac, France; Matthew Hansen, MD, of Banner Gateway Medical Center in Gilbert, Ariz.; Raymond Klug, MD, of Lakewood Regional Medical Center in Lakewood, Calif.; and Joseph D. Zuckerman, MD, of NYU Langone Orthopedic Hospital in New York City.

 

SourceExactech

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”